The purpose of this study is to evaluate the safety, efficacy and tolerability of subcutaneous (SC) blinatumomab for treatment of acute lymphoblastic leukemia and to determine the maximum tolerated dose and preliminary recommended phase 2 dose(s) of SC administered blinatumomab.
The purpose of this study is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor. The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias or incident heart failure.
The purpose of this study is to compare the standard of care therapy (VRd + Rd therapy) and CAR-T therapy (VRd + CAR-T) for newly diagnosed multiple myeloma patients who do not plan to receive hematopoietic stem cell transplant as initial therapy.
The purpose of this study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP), who have previously been treated with at least 2 tyrosine kinase inhibitors. Additionally, this study will investigate the usage of two different dosing regimes of asciminib, 80mg daily and 40mg twice daily.
The purpose of this study is to identify inheritable mutations among male breast cancer participants by performing genetic testing on their cancer samples, instead of blood samples (such as tumour testing). This testing will allow researchers to identify inheritable mutations when blood samples are not available. This study will evaluate the clinical utility and the feasibility of offering the tumour testing in newly diagnosed male breast cancer patients.
The purpose of this study is to evaluate the effect of a peer navigation program for men with prostate and a peer navigator training course called the True North Peer Navigation program. The study will evaluate patient outcomes such as their ability to take a more active role in their health, quality of life, social support and use of health care services, in addition to the experiences of patients and peer navigators and the factors that make it easier or harder for people to deliver the program to patients in different settings.
The purpose of this study is to understand how to assess for shoulder and arm problems women may experience related to breast cancer and its treatment and to help women know when it may be appropriate to seek physiotherapy care.
The purpose of this study is to determine whether a reduced dose of apixaban is non-inferior to and safer than the full dose of apixaban for the prevention of recurrent venous thromboembolism (VTE) in active cancer patients.
The purpose of this study is to evaluate the safety and efficacy of CC-97540 CAR-T cell treatment for subjects with relapsed or refractory B-cell non-Hodgkin lymphoma.
The purpose of this study is to compare the efficacy of the drugs ponatinib versus imatinib, administered as first-line therapy in combination with reduced-intensity chemotherapy, in participants with newly diagnosed Ph+ ALL, as measured by the minimal residual disease (MRD)-negative complete remission (CR) at the end of induction.
The purpose of this study is to evaluate the impact of an aerobic exercise intervention on Chemotherapy-Related Cognitive Changes (CRCC) in women diagnosed with breast cancer who undergo chemotherapy.
The purpose of the study is to test the safety and efficacy of a drug known as CC-220 in combination with other treatments for multiple myeloma patients.
The purpose of this study is to investigate the safety and efficacy of the drug MBG453 as treatment for newly diagnosed Acute Myeloid Leukemia patients when used in combination with other anti-cancer treatments.
The purpose of this study is to evaluate the safety and tolerability of AMG 160; a half-life extended (HLE) bispecific T-cell engager (BiTE®) antibody construct, alone and in combination with pembrolizumab in subjects with metastatic castration-resistant prostate cancer.
This study is an longitudinal observation study to enroll patients who have chronic graft versus host host disease and are about to receive initial or second line treatment, in order to identify predictors of treatment response.
Prostate Cancer Survivorship 360º is a collaboration-based initiative involving prostate cancer (PC) and survivorship researchers/clinicians from three Canadian prostate centers with the goal of identifying and tracking unmet supportive care needs of patients with localized PC and responding to these needs through survivorship care. The current randomized control trail (RCT) will focus on the development and evaluation of a facilitated electronic Prostate Cancer Survivorship Care Plan (PC-SCP).
People who may be at increased risk of lung cancer due to age and smoking history will be invited to participate in this international study to determine the best way of using computed tomography (CT) of the chest to screen for early lung cancer. Overseas data show that CT screening (screening tests can find diseases early, when they're easier to treat) can reduce deaths from lung cancer and this study will help determine who is most likely benefit from screening.
This study will maximize identification of women with Lynch Syndrome using an enhanced screening strategy to identify those at risk. These women will be referred to genetic counselling for testing and those found to have Lynch Syndrome will be asked to invite first degree relatives to participate and undergo genetic testing for Lynch Syndrome.
This pilot study will investigate the impact of dexamethasone (DEX) on anti-Xa levels in participants taking apixaban 2.5 mg twice a day by mouth (PO BID). Investigators propose a prospective, cohort study of 24 participants with multiple myeloma, in whom a lenalidomide-dexamethasone (LEN-DEX)-based myeloma treatment regimen is indicated. Eligible participants will initiate thromboprophylaxis with apixaban prior to starting their DEX-containing regimen and continue until the end of cycle 3. Anti-Xa levels, D-Dimer and plasma drug concentration will be measured.
Imatinib (IM) is first-line treatment for patients with newly diagnosed CML in chronic phase. The drug is associated with high rates of cytogenetic responses with minimal toxicity in approximately 80% of patients. In 20% of patients however, the disease is either initially unresponsive to IM (Imatinib), resistance develops within a few months, or blast crisis occurs early and unexpectedly following an initial response.